Fig 1: mRNA level of IL-21 (a) and IL-21R (b) in muscle tissue of patients with DM/PM and controls. The data showed that mRNA level of IL-21 was higher in patients with DM/PM than in controls (a). Comparison of IL-21 mRNA expression between groups: DM versus control, *P = 0.001; PM versus control, †P = 0.001. The mRNA level of IL-21R was not higher in patients with DM/PM than in controls; (b). IL-21: Interleukin 21; IL-21R: Interleukin 21 receptor; DM: Dermatomyositis; PM: Polymyositis.
Fig 2: Immunohistochemistry analysis of IL-21 and IL-21R expression in muscle tissues of patients with DM/PM. (a, b, e, and f) The expression of IL-21 and IL-21R in a patient with DM. (a and e) H and E staining. (b) IL-21 staining. (f) IL-21R staining. IL-21 and IL-21R were expressed in the perivascular lymphocytes (original magnification ×400). (c, d, g and h) The expression of IL-21 and IL-21R in a patient with PM. (c and g) H and E staining, (d) IL-21 staining, (h) IL-21R staining. IL-21 and IL-21R were mainly detected in the lymphocytes surrounding the muscle fibers (original magnification ×400). IL-21: Interleukin 21; IL-21R: Interleukin 21 receptor; DM: Dermatomyositis; PM: Polymyositis.
Fig 3: Serum level of IL-21 in patients with DM/PM and controls. The concentration of serum IL-21 was higher in patients with DM/PM than in healthy controls (comparison of serum IL-21 level, DM vs. control, *P = 0.001; PM vs. control, †P = 0.005). IL-21: Interleukin 21; DM: Dermatomyositis; PM: Polymyositis.
Supplier Page from BioLegend for LEGEND MAX(TM) Human IL-21 ELISA Kit